These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 23797798

  • 1. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun 24; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract] [Full Text] [Related]

  • 2. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
    Med Lett Drugs Ther; 2014 Jun 23; 56(1445):51-2. PubMed ID: 24956309
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F.
    Rev Med Liege; 2013 Sep 23; 68(9):486-8. PubMed ID: 24180205
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.
    Pediatr Pulmonol; 2007 Apr 23; 42(4):307-13. PubMed ID: 17352404
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.
    N Engl J Med; 1999 Jan 07; 340(1):23-30. PubMed ID: 9878641
    [Abstract] [Full Text] [Related]

  • 10. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG, Gembitskaia TE.
    Ter Arkh; 2010 Jan 07; 82(8):76-8. PubMed ID: 20873251
    [Abstract] [Full Text] [Related]

  • 11. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL.
    Paediatr Drugs; 2007 Jan 07; 9 Suppl 1():11-20. PubMed ID: 17536871
    [Abstract] [Full Text] [Related]

  • 12. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
    Chuchalin A, Amelina E, Bianco F.
    Pulm Pharmacol Ther; 2009 Dec 07; 22(6):526-32. PubMed ID: 19616111
    [Abstract] [Full Text] [Related]

  • 13. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.
    Respir Care; 2014 Mar 07; 59(3):388-98. PubMed ID: 23983274
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R, Parkins MD.
    Ther Deliv; 2015 Feb 07; 6(2):121-37. PubMed ID: 25690082
    [Abstract] [Full Text] [Related]

  • 17. [Anti-Pseudomonas aerosol therapy in cystic fibrosis: improvement with tobramycin].
    Foucaud P, Borel B, Charara O, Nathanson S, Petitprez P, Pin I.
    Rev Pneumol Clin; 2002 Jun 07; 58(3 Pt 1):131-8. PubMed ID: 12486796
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.